Market Cap: $183.75M
AI
Akebia Therapeutics, Inc.
AKBA
NASDAQ (NASDAQ Global Market)USD
Market Cap: $183.75M
Akebia Therapeutics Strengthens Focus on Vafseo Commercialization Akebia Therapeutics (Ticker: AKBA) focuses on its commercial strategy for Vafseo, an anemia treatment for chronic kidney disease, as o…
Akebia Therapeutics: Innovations Amid Growth in the Health Sector Akebia Therapeutics, a player in the biopharmaceutical industry, remains focused on developing and commercializing innovative therapie…
Akebia Therapeutics Prepares for Quarterly Earnings Amid Analyst Scrutiny As Akebia Therapeutics gears up to announce its quarterly earnings report on February 26, 2026, the focus is on the company’s…
Akebia Therapeutics' Strategic Focus on Chronic Kidney Disease: Implications for Future Growth Akebia Therapeutics is at a pivotal moment as it prepares to unveil its quarterly earnings report on Febr…
Akebia Therapeutics' Focus on Chronic Kidney Disease Innovation Akebia Therapeutics (NASDAQ: AKBA) is poised to impact the landscape of renal therapeutics, particularly as it preps for its quarterly e…
Akebia Therapeutics Expands Portfolio with Acquisition of ADX-097 from Q32 Bio Akebia Therapeutics, Inc. has recently acquired ADX-097, a Phase 2 complement inhibitor, from Q32 Bio Inc., a strategic m…
Akebia Therapeutics Acquires Complement Inhibitor from Q32 Bio to Broaden Therapeutic Portfolio Akebia Therapeutics, a biotechnology company focused on innovative treatments for kidney diseases, makes…
Akebia Therapeutics Expands Its Portfolio through Acquisition of ADX-097 Akebia Therapeutics, Inc., a prominent player in the biotechnology sector, has made a strategic move by acquiring ADX-097, a Ph…
Akebia Therapeutics: Advancements in Kidney Disease Treatments Akebia Therapeutics focuses on developing innovative therapies for patients with kidney disease, particularly through its lead product, v…
Akebia Therapeutics: Advancing Kidney Health with Innovative Therapeutics Akebia Therapeutics is at the forefront of developing innovative therapies for patients with kidney disease, particularly focu…
Akebia Therapeutics Prepares for Key Quarterly Earnings Report Akebia Therapeutics, a biotechnology firm focused on innovative treatments for kidney disease, is poised to release its quarterly earning…
Akebia Therapeutics Prepares for Key Quarterly Earnings Report Akebia Therapeutics is poised to release its quarterly earnings report on November 10, 2025, a moment that is generating significant inte…
Akebia Therapeutics Faces Challenges Amidst Competitive Biopharmaceutical Landscape Akebia Therapeutics Inc. is currently navigating a complex environment as it advances its lead product candidate, va…
Akebia Therapeutics Navigates Regulatory Challenges in Anemia Treatment Development Akebia Therapeutics Inc. is currently addressing significant challenges in the development of its lead product candi…
Akebia Therapeutics: Navigating Challenges in Chronic Kidney Disease Treatment Akebia Therapeutics Inc. faces significant hurdles in its quest to advance treatments for anemia associated with chronic…
Akebia Therapeutics: Advancements in Anemia Treatment and Market Strategy Akebia Therapeutics is on the cusp of revealing its quarterly earnings, with a significant focus on its flagship product, vada…
Anticipation Builds for Akebia Therapeutics' Earnings Announcement As Akebia Therapeutics prepares to announce its quarterly earnings on August 7, 2025, stakeholders are keenly focused on the company'…
Akebia Therapeutics: Advancements in Anemia Treatment and Strategic Growth As Akebia Therapeutics approaches its quarterly earnings announcement on August 7, 2025, the focus remains squarely on the co…
Emerging Tools in Cryptocurrency Trading: Whale Alert Enhances Market Transparency In the rapidly evolving world of cryptocurrency, traders constantly seek tools that provide them with a competitive e…